Available IPD datapackage for study 'A Phase III, Open-Label, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Bevacizumab Versus Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma'
收藏DataCite Commons2025-02-25 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/dataPackages/PR00005997.12
下载链接
链接失效反馈官方服务：
资源简介：
This multi-center, randomized, open-label study will evaluate the efficacy and safety of atezolizumab plus bevacizumab versus sunitinib in participants with inoperable, locally advanced, or metastatic RCC who have not received prior systemic active or experimental therapy, either in the adjuvant or metastatic setting.
提供机构：
Vivli
创建时间：
2025-02-25
